<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9032320</article-id><article-id pub-id-type="doi">10.3390/antibiotics11040438</article-id><article-id pub-id-type="publisher-id">antibiotics-11-00438</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Biosynthesis and Chemical Synthesis of Albomycin Nucleoside Antibiotics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Meiyan</given-names></name><xref rid="af1-antibiotics-11-00438" ref-type="aff">1</xref><xref rid="af2-antibiotics-11-00438" ref-type="aff">2</xref><xref rid="af3-antibiotics-11-00438" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuxin</given-names></name><xref rid="af1-antibiotics-11-00438" ref-type="aff">1</xref><xref rid="af2-antibiotics-11-00438" ref-type="aff">2</xref><xref rid="af3-antibiotics-11-00438" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Lv</surname><given-names>Lanxin</given-names></name><xref rid="af1-antibiotics-11-00438" ref-type="aff">1</xref><xref rid="af2-antibiotics-11-00438" ref-type="aff">2</xref><xref rid="af3-antibiotics-11-00438" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Dekun</given-names></name><xref rid="af1-antibiotics-11-00438" ref-type="aff">1</xref><xref rid="af2-antibiotics-11-00438" ref-type="aff">2</xref><xref rid="af3-antibiotics-11-00438" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4796-5630</contrib-id><name><surname>Niu</surname><given-names>Guoqing</given-names></name><xref rid="af1-antibiotics-11-00438" ref-type="aff">1</xref><xref rid="af2-antibiotics-11-00438" ref-type="aff">2</xref><xref rid="af3-antibiotics-11-00438" ref-type="aff">3</xref><xref rid="c1-antibiotics-11-00438" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Aparicio</surname><given-names>Jes&#x000fa;s F.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antibiotics-11-00438"><label>1</label>Biotechnology Research Center, Southwest University, Chongqing 400715, China; <email>swuwmy@email.swu.edu.cn</email> (M.W.); <email>zhangyx950@email.swu.edu.cn</email> (Y.Z.); <email>l188165@email.swu.edu.cn</email> (L.L.); <email>kongdekun@swu.edu.cn</email> (D.K.)</aff><aff id="af2-antibiotics-11-00438"><label>2</label>Chongqing Key Laboratory of Plant Resource Conservation and Germplasm Innovation, Southwest University, Chongqing 400715, China</aff><aff id="af3-antibiotics-11-00438"><label>3</label>State Cultivation Base of Crop Stress Biology for Southern Mountainous Land, Academy of Agricultural Sciences, Southwest University, Chongqing 400715, China</aff><author-notes><corresp id="c1-antibiotics-11-00438"><label>*</label>Correspondence: <email>niu062376@swu.edu.cn</email>; Tel.: +86-23-6825-1883</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>3</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2022</year></pub-date><volume>11</volume><issue>4</issue><elocation-id>438</elocation-id><history><date date-type="received"><day>01</day><month>3</month><year>2022</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The widespread emergence of antibiotic-resistant bacteria highlights the urgent need for new antimicrobial agents. Albomycins are a group of naturally occurring sideromycins with a thionucleoside antibiotic conjugated to a ferrichrome-type siderophore. The siderophore moiety serves as a vehicle to deliver albomycins into bacterial cells via a &#x0201c;Trojan horse&#x0201d; strategy. Albomycins function as specific inhibitors of seryl-tRNA synthetases and exhibit potent antimicrobial activities against both Gram-negative and Gram-positive bacteria, including many clinical pathogens. These distinctive features make albomycins promising drug candidates for the treatment of various bacterial infections, especially those caused by multidrug-resistant pathogens. We herein summarize findings on the discovery and structure elucidation, mechanism of action, biosynthesis and immunity, and chemical synthesis of albomcyins, with special focus on recent advances in the biosynthesis and chemical synthesis over the past decade (2012&#x02013;2022). A thorough understanding of the biosynthetic pathway provides the basis for pathway engineering and combinatorial biosynthesis to create new albomycin analogues. Chemical synthesis of natural congeners and their synthetic analogues will be useful for systematic structure&#x02013;activity relationship (SAR) studies, and thereby assist the design of novel albomycin-derived antimicrobial agents.</p></abstract><kwd-group><kwd>antibiotic resistance</kwd><kwd>albomycin</kwd><kwd>mode of action</kwd><kwd>biosynthesis</kwd><kwd>self-resistance</kwd><kwd>chemical synthesis</kwd><kwd>antimicrobial agents</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-11-00438"><title>1. Introduction</title><p>The emergence and rapid spread of antibiotic resistance among pathogens has become a major healthcare problem worldwide. This problem becomes even worse with a coincident decline in the supply of novel antimicrobial agents [<xref rid="B1-antibiotics-11-00438" ref-type="bibr">1</xref>,<xref rid="B2-antibiotics-11-00438" ref-type="bibr">2</xref>]. Therefore, there is an urgent need for the discovery and development of novel antimicrobial drugs that either act on new cellular targets or bypass the development of resistance. Natural products offer a great variety of chemical diversity with distinctive biological activities. It is estimated that more than half of approved drugs, from the period of 1981 to 2019, are either natural products or derivatives thereof [<xref rid="B3-antibiotics-11-00438" ref-type="bibr">3</xref>]. Thus, natural products remain the most promising sources for drug discovery and development [<xref rid="B4-antibiotics-11-00438" ref-type="bibr">4</xref>,<xref rid="B5-antibiotics-11-00438" ref-type="bibr">5</xref>]. In recent years, aminoacyl-tRNA synthetases (aaRSs) have emerged as attractive targets for the development of novel antimicrobial drugs [<xref rid="B6-antibiotics-11-00438" ref-type="bibr">6</xref>]. To ensure the fidelity of protein synthesis, these enzymes catalyze the charging of tRNA with cognate amino acids in a two-step process [<xref rid="B7-antibiotics-11-00438" ref-type="bibr">7</xref>]. The first step involves formation of an aminoacyl&#x02013;adenylate (aa-AMP) intermediate with concomitant release of pyrophosphate (PP<sub>i</sub>). In the second step, the aminoacyl moiety is transferred to the 3&#x02032;-terminal adenosine of the cognate tRNA (<xref rid="antibiotics-11-00438-sch001" ref-type="fig">Scheme 1</xref>). The 20 aaRSs have been classified into two classes: Class &#x02160; and Class &#x02161;, mainly based on the structures of their active sites [<xref rid="B7-antibiotics-11-00438" ref-type="bibr">7</xref>]. Considering the vital role of aaRSs in protein synthesis, it is reasonable to expect that inhibition of these enzymes is detrimental to cell survival. </p><p>Sideromycins are a unique subset of siderophores that are comprised of an antibacterial moiety covalently linked to a siderophore. They are actively transported into bacterial cells via a &#x0201c;Trojan horse&#x0201d; strategy by hijacking the siderophore uptake pathway, that is commonly used by bacteria to scavenge environmental iron [<xref rid="B8-antibiotics-11-00438" ref-type="bibr">8</xref>]. These siderophore-antibiotic conjugates are promising drug candidates for the treatment of various bacterial infections, including those caused by multidrug-resistant pathogens. Over the past few decades, only a few naturally occurring sideromycins, such as albomycins, salmycins, and ferrimycins, have been identified [<xref rid="B8-antibiotics-11-00438" ref-type="bibr">8</xref>,<xref rid="B9-antibiotics-11-00438" ref-type="bibr">9</xref>]. Of particular interest are albomycins that function as inhibitors of bacterial seryl-tRNA synthetase (SerRS). Examples of other aaRSs inhibitors include microcin C and agrocin 84 (<xref rid="antibiotics-11-00438-f001" ref-type="fig">Figure 1</xref>), targeting aspartyl tRNA synthetase (AspRS) and leucyl-tRNA synthetase (LeuRS), respectively [<xref rid="B10-antibiotics-11-00438" ref-type="bibr">10</xref>]. The biosynthesis, mode of action and self-resistance of microcin C have been reviewed comprehensively [<xref rid="B10-antibiotics-11-00438" ref-type="bibr">10</xref>,<xref rid="B11-antibiotics-11-00438" ref-type="bibr">11</xref>]. At present, our understanding on synthesis, mode of action and self-resistance of agrocin 84 is still limited [<xref rid="B12-antibiotics-11-00438" ref-type="bibr">12</xref>,<xref rid="B13-antibiotics-11-00438" ref-type="bibr">13</xref>]. In this review, we summarize findings on the discovery and structure elucidation, mode of action, biosynthesis, self-resistance, and chemical synthesis of albomycins.</p></sec><sec id="sec2-antibiotics-11-00438"><title>2. Discovery and Structure Elucidation</title><p>Albomycin, originally designated as grisein, was first isolated from the soil-dwelling <italic toggle="yes">Streptomyces griseus</italic> in the 1940s [<xref rid="B14-antibiotics-11-00438" ref-type="bibr">14</xref>,<xref rid="B15-antibiotics-11-00438" ref-type="bibr">15</xref>]. It was also identified in <italic toggle="yes">Streptomyces subtropicus</italic> (previously known as <italic toggle="yes">Actinomyces subtropicus</italic>) [<xref rid="B16-antibiotics-11-00438" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-11-00438" ref-type="bibr">17</xref>]. It is noteworthy that albomycin was also known as alveomycin, antibiotics A 1787, LA 5352 and LA 5937, and Ro 5-2667 in the literature [<xref rid="B18-antibiotics-11-00438" ref-type="bibr">18</xref>,<xref rid="B19-antibiotics-11-00438" ref-type="bibr">19</xref>]. Thirty-five years after the initial isolation, chemical structures of three albomycin congeners (&#x003b4;<sub>1</sub>, &#x003b4;<sub>2</sub>, and &#x003b5;) were fully elucidated by Benz and coworkers in 1982 [<xref rid="B20-antibiotics-11-00438" ref-type="bibr">20</xref>,<xref rid="B21-antibiotics-11-00438" ref-type="bibr">21</xref>]. The albomycins are composed of a ferrichrome-type siderophore and a 6&#x02032;-amino-4&#x02032;-thioheptose nucleoside that are linked via amide linkages to a serine residue (<xref rid="antibiotics-11-00438-f001" ref-type="fig">Figure 1</xref>). The siderophore moiety consists of three tandem <italic toggle="yes">N</italic><sup>5</sup>-acetyl-<italic toggle="yes">N</italic><sup>5</sup>-hydroxy-L-ornithine residues, mimicking the siderophore ferrichrome from fungi [<xref rid="B22-antibiotics-11-00438" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-11-00438" ref-type="bibr">23</xref>]. The most striking feature of the nucleoside moiety is the substitution of a sulfur atom for an oxygen atom on the pentose ring, that is most commonly found in other nucleoside antibiotics, such as liposidomycin, caprazamycin, muraymycin, muraminomicin, and A-90289 [<xref rid="B24-antibiotics-11-00438" ref-type="bibr">24</xref>,<xref rid="B25-antibiotics-11-00438" ref-type="bibr">25</xref>]. It is worth noting that the three albomycin congeners differ mainly in the C<sub>4</sub> substituent of the pyrimidine nucleoside (<xref rid="antibiotics-11-00438-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec3-antibiotics-11-00438"><title>3. Mechanism of Action</title><p>Albomycins have attracted significant attention due to their potent antibacterial activities against both Gram-negative and Gram-positive bacteria [<xref rid="B15-antibiotics-11-00438" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-11-00438" ref-type="bibr">16</xref>,<xref rid="B26-antibiotics-11-00438" ref-type="bibr">26</xref>]. For example, the major congener &#x003b4;<sub>2</sub> exhibited minimum inhibitory concentrations (MICs) as low as 5 ng/mL against <italic toggle="yes">Escherichia coli</italic> and 10 ng/mL against <italic toggle="yes">Streptococcus pneumoniae</italic> [<xref rid="B27-antibiotics-11-00438" ref-type="bibr">27</xref>]. The excellent antibacterial activities of albomycins were attributed to their ability to hijack the ferric hydroxamate transport system and gain access to bacterial cells. For illustration purposes, we herein only briefly highlight current understanding on active uptake of albomycins in <italic toggle="yes">E. coli</italic> and <italic toggle="yes">S. pneumoniae</italic>. Readers interested in other bacteria species are referred to two recent reviews [<xref rid="B10-antibiotics-11-00438" ref-type="bibr">10</xref>,<xref rid="B28-antibiotics-11-00438" ref-type="bibr">28</xref>]. In <italic toggle="yes">E. coli</italic>, transport across the outer membrane is facilitated by a ferrichrome receptor FhuA [<xref rid="B29-antibiotics-11-00438" ref-type="bibr">29</xref>], while transport across the cytoplasmic membrane is mediated by a ABC transporter FhuBCD [<xref rid="B30-antibiotics-11-00438" ref-type="bibr">30</xref>]. FhuA consists of an N-terminal cork domain and a C-terminal transmembrane &#x003b2;-barrel domain. Binding of a ligand promotes the FhuA interaction with TonB, which in turn stimulates a rearrangement of the cork domain and the release of the ligand into the periplasmic space [<xref rid="B31-antibiotics-11-00438" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-11-00438" ref-type="bibr">32</xref>]. Once translocated into the periplasm, albomycin is bound by the periplasmic binding protein FhuD [<xref rid="B33-antibiotics-11-00438" ref-type="bibr">33</xref>]. The antibiotic is then shuttled to the inner membrane ABC transporter FhuBC, and actively transported into the cytoplasm [<xref rid="B34-antibiotics-11-00438" ref-type="bibr">34</xref>]. In <italic toggle="yes">E. coli</italic>, all genes encoding the transporter system are organized within the <italic toggle="yes">fhuABCD</italic> operon. Bacterial strains with mutations in any of these genes lost the ability to ingest albomycins and thus are resistant to their antimicrobial effects [<xref rid="B35-antibiotics-11-00438" ref-type="bibr">35</xref>]. A similar transporter system was also characterized in <italic toggle="yes">S. pneumoniae</italic> [<xref rid="B27-antibiotics-11-00438" ref-type="bibr">27</xref>]. The transporter system was encoded by the <italic toggle="yes">fhu</italic> locus consisting of <italic toggle="yes">fhuD</italic>, <italic toggle="yes">fhuB</italic>, <italic toggle="yes">fhuG</italic>, and <italic toggle="yes">fhuC</italic>. The <italic toggle="yes">fhuD</italic> encodes a binding lipoprotein, that is thought to be responsible for substrate recognition. The <italic toggle="yes">fhuB</italic> and <italic toggle="yes">fhuG</italic> encode transmembrane transport proteins, while the <italic toggle="yes">fhuC</italic> encodes an ATPase that presumably provides energy for transmembrane uptake [<xref rid="B27-antibiotics-11-00438" ref-type="bibr">27</xref>]. Upon entry into the cell, albomycins will be hydrolyzed by host peptidases to release the thionucleoside warhead, referred to as SB-217452, from the iron-chelating siderophore moiety [<xref rid="B36-antibiotics-11-00438" ref-type="bibr">36</xref>]. The SB-217452 resembles seryl adenylate, and selectively inhibits seryl-tRNA synthetases (SerRSs), and thereby interfering with host protein synthesis [<xref rid="B27-antibiotics-11-00438" ref-type="bibr">27</xref>]. Thus, the potent antimicrobial activities of albomycins are attributed to the ferrichrome-mediated active uptake and subsequent liberation of the toxic thionucleoside SB-217452.</p></sec><sec id="sec4-antibiotics-11-00438"><title>4. Biosynthetic Pathway</title><p>Albomycins are endowed with unique structural features, suggesting the occurrence of unusual enzymatic reactions during the biosynthetic process. To gain insight into this biosynthetic pathway, the gene cluster for albomycin biosynthesis has been identified by screening a cosmid library of <italic toggle="yes">S. griseus</italic> ATCC 700974 [<xref rid="B37-antibiotics-11-00438" ref-type="bibr">37</xref>]. The gene cluster consists of 25 complete open reading frames (ORFs) including ORFs 1&#x02013;7 and 18 genes from <italic toggle="yes">abmA</italic> to <italic toggle="yes">abmR</italic> (<xref rid="antibiotics-11-00438-f002" ref-type="fig">Figure 2</xref>A). It was proposed that the 18 genes from <italic toggle="yes">abmA</italic> to <italic toggle="yes">abmR</italic> are required for albomycin production, while ORFs 1&#x02013;7 are not involved in albomycin biosynthesis [<xref rid="B37-antibiotics-11-00438" ref-type="bibr">37</xref>]. A few recent studies have been directed to elucidate biosynthetic process of the thionucleoside SB-217452 [<xref rid="B37-antibiotics-11-00438" ref-type="bibr">37</xref>,<xref rid="B38-antibiotics-11-00438" ref-type="bibr">38</xref>,<xref rid="B39-antibiotics-11-00438" ref-type="bibr">39</xref>]. These studies established that the formation of SB-217452 proceeds through complex enzymatic reactions with the participation of AbmH, AbmD, AbmF, AbmK, and AbmJ (<xref rid="antibiotics-11-00438-f002" ref-type="fig">Figure 2</xref>B). AbmH is a pyridoxal 5&#x02032;-phosphate (PLP)-dependent transaldolase responsible for catalyzing a <italic toggle="yes">threo</italic>-selective aldol-type reaction to generate the thioheptose core with a D-ribofuranose ring and an L-amino acid moiety. Subsequently, the conversion of L- to D-amino acid configuration is achieved through the action of a PLP-dependent epimerase (AbmD) [<xref rid="B38-antibiotics-11-00438" ref-type="bibr">38</xref>]. Then, an aminoacyl-tRNA synthetase (AbmF) catalyzes condensation between the 6&#x02032;-amino-4&#x02032;-thionucleoside and the D-ribo configuration and seryl-adenylate. Of note is that the seryl-adenylate appears to be supplied by the seryl-tRNA synthetase (AbmK). The D-<italic toggle="yes">ribo</italic> to D-<italic toggle="yes">xylo</italic> conversion of the thiofuranose ring is thought to be catalyzed by a radical S-adenosyl-L-methionine (SAM) enzyme (AbmJ) [<xref rid="B38-antibiotics-11-00438" ref-type="bibr">38</xref>,<xref rid="B39-antibiotics-11-00438" ref-type="bibr">39</xref>]. It is interesting to note that AbmK directly participates in the formation of SB-217452 by providing a substrate for albomycin biosynthesis. Similarly, a gene (<italic toggle="yes">vlmL</italic>) encoding a class II seryl-tRNA synthetase was also identified within the gene cluster for valanimycin biosynthesis in <italic toggle="yes">Streptomyces viridifaciens</italic>. Studies revealed that this seryl-tRNA synthetase is responsible for catalyzing seryl transfer in the valanimycin biosynthetic pathway [<xref rid="B40-antibiotics-11-00438" ref-type="bibr">40</xref>,<xref rid="B41-antibiotics-11-00438" ref-type="bibr">41</xref>]. Furthermore, two enzymes, a <italic toggle="yes">N</italic>-methyltransferase (AbmI) and a carbamoyltransferase (AbmE), have been identified to be responsible for the tailoring modifications of <italic toggle="yes">N</italic><sup>3</sup>-methylation and <italic toggle="yes">N</italic><sup>4</sup>-carbamoylation of cytidine [<xref rid="B37-antibiotics-11-00438" ref-type="bibr">37</xref>]. Although significant progress has been made in uncovering biosynthetic machinery of SB-217452, the order of known steps needs further clarification. Moreover, many details of its biosynthesis remain elusive. For example, it remains a mystery how the characteristic sulfur atom is incorporated in <bold>6</bold>. Thus, more genetic and biochemical studies are required to reveal the complex process.</p><p>As mentioned above, the presence of the ferrichrome-type siderophore allows active transport of albomycin into bacterial cells. It was hypothesized that three genes, <italic toggle="yes">abmA</italic>, <italic toggle="yes">abmB</italic>, and <italic toggle="yes">abmQ</italic>, are responsible for the formation of the ferrichrome siderophore [<xref rid="B37-antibiotics-11-00438" ref-type="bibr">37</xref>]. The pathway is initiated by the <italic toggle="yes">N</italic><sup>5</sup> hydroxylation of L-ornithine to <italic toggle="yes">N</italic><sup>5</sup>-hydroxy-L-ornithine, catalyzed by a flavin-dependent ornithine monooxygenase (AbmB). Subsequently, <italic toggle="yes">N</italic><sup>5</sup>-hydroxy-L-ornithine is converted to <italic toggle="yes">N</italic><sup>5</sup>-acetyl-<italic toggle="yes">N</italic><sup>5</sup>-hydroxy-L-ornithine through the action of an N-acyltransferase (AbmA). Three molecules of <italic toggle="yes">N</italic><sup>5</sup>-acetyl-<italic toggle="yes">N</italic><sup>5</sup>-hydroxy-L-ornithine are then used by, AbmQ, a nonribosomal peptide synthetase (NRPS), for iterative condensation to generate the tripeptide (<xref rid="antibiotics-11-00438-f002" ref-type="fig">Figure 2</xref>B). Sequence analysis suggested that AbmQ contains one adenylating (A) domain, two condensation (C) domains, and three thiolation (T) domains (<xref rid="antibiotics-11-00438-f002" ref-type="fig">Figure 2</xref>B). The presence of a single adenylating domain is a unique feature of AbmQ, implying that this domain supplies substrates for both condensation domains [<xref rid="B37-antibiotics-11-00438" ref-type="bibr">37</xref>,<xref rid="B39-antibiotics-11-00438" ref-type="bibr">39</xref>]. Furthermore, a typical NRPS contains a C-terminal thioesterase (TE) domain to catalyze hydrolysis of the thioester intermediate to release the peptide product from the phosphopantetheine group linked to the peptidyl carrier protein (PCP) domain [<xref rid="B42-antibiotics-11-00438" ref-type="bibr">42</xref>]. However, AbmQ lacks a C-terminal TE domain. This atypical domain organization implies that no free siderophore is released from AbmQ and that the thioester intermediate may directly serve as the electrophile in the subsequent amide bond formation with either SB-217452 or L-serine. Genetic studies suggest that AbmC may participate in this amide bond formation [<xref rid="B39-antibiotics-11-00438" ref-type="bibr">39</xref>]. However, biochemical evidence is needed to clarify its function. It is noteworthy that the biosynthetic pathway for the ferrichrome-type siderophore in albomycin has been proposed based on putative functions of associated genes. Further experimental evidence is definitely needed to support this assumption.</p></sec><sec id="sec5-antibiotics-11-00438"><title>5. Self-Resistance</title><p>Typically, self-resistance is a prerequisite for antibiotic-producing bacteria. They have evolved a variety of mechanisms to ensure protection from self-made cytotoxic compounds. This is particularly true for the bacterial genus <italic toggle="yes">Streptomyces</italic>, prolific producers of antibiotics and many other bioactive secondary metabolites. The thionucleoside SB-217452 exhibits its antimicrobial activity by targeting SerRS. SerRS belongs to the class-II family of aminoacyl-tRNA synthetases (aaRSs) [<xref rid="B43-antibiotics-11-00438" ref-type="bibr">43</xref>]. These enzymes catalyze the attachment of amino acids to their corresponding tRNAs [<xref rid="B7-antibiotics-11-00438" ref-type="bibr">7</xref>]. Due to the pivotal role of aaRSs in the protein synthesis, inhibition of a member of this family is detrimental to cell viability. It is conceivable that the compound is also toxic to the natural producer. One early study identified two SerRS encoding genes (<italic toggle="yes">serS1</italic> and <italic toggle="yes">serS2</italic>) in the genome of albomycin-producing strain <italic toggle="yes">S. griseus</italic> ATCC 700974 [<xref rid="B44-antibiotics-11-00438" ref-type="bibr">44</xref>]. Sequence analysis suggested that <italic toggle="yes">serS1</italic> encodes a housekeeping SerRS, while <italic toggle="yes">serS2</italic> encodes a SerRS that is significantly divergent from SerRS1. Of note is that <italic toggle="yes">serS2</italic> is located within the gene cluster for albomycin biosynthesis, thus it is designated as <italic toggle="yes">abmK</italic> [<xref rid="B37-antibiotics-11-00438" ref-type="bibr">37</xref>]. However, <italic toggle="yes">serS1</italic> is situated elsewhere in the chromosome. When heterologously overexpressed in <italic toggle="yes">E. coli</italic> JM109, <italic toggle="yes">serS2</italic> (<italic toggle="yes">abmK</italic>) confers immunity to albomycin in vivo, while <italic toggle="yes">serS1</italic> fails to do so. Furthermore, SerRS2 was specifically resistant to SB-217452 in vitro [<xref rid="B44-antibiotics-11-00438" ref-type="bibr">44</xref>]. A similar phenomenon has also been reported for other natural aaRSs inhibitors, such as mupirocin (isoleucyl-tRNA synthetases inhibitor) [<xref rid="B45-antibiotics-11-00438" ref-type="bibr">45</xref>], borrelidin (threonyl-tRNA synthetase inhibitor) [<xref rid="B46-antibiotics-11-00438" ref-type="bibr">46</xref>], and agrocin 84 (leucyl-tRNA synthetase inhibitor) [<xref rid="B13-antibiotics-11-00438" ref-type="bibr">13</xref>].</p><p>It is not uncommon that antibiotic-producing bacteria duplicate genes encoding target proteins to confer resistance [<xref rid="B45-antibiotics-11-00438" ref-type="bibr">45</xref>,<xref rid="B47-antibiotics-11-00438" ref-type="bibr">47</xref>,<xref rid="B48-antibiotics-11-00438" ref-type="bibr">48</xref>,<xref rid="B49-antibiotics-11-00438" ref-type="bibr">49</xref>]. It is noteworthy that some resistance genes may be situated within or adjacent to the gene clusters for antibiotic biosynthesis. Based on these observations, resistance-guided genome mining strategy has been devised and used successfully for the discovery of novel antimicrobial agents [<xref rid="B1-antibiotics-11-00438" ref-type="bibr">1</xref>,<xref rid="B2-antibiotics-11-00438" ref-type="bibr">2</xref>,<xref rid="B49-antibiotics-11-00438" ref-type="bibr">49</xref>,<xref rid="B50-antibiotics-11-00438" ref-type="bibr">50</xref>]. Previous studies suggest that AbmK plays dual role in the biosynthesis and immunity of albomycins. A recent study indicated that AbmK participates directly in the formation of SB-217452 during biosynthesis of albomycins [<xref rid="B39-antibiotics-11-00438" ref-type="bibr">39</xref>]. In the meantime, AbmK confers resistance to albomycins to avoid suicide [<xref rid="B44-antibiotics-11-00438" ref-type="bibr">44</xref>]. Thus, <italic toggle="yes">abmK</italic> is a good candidate to be used as a query to search for homologues that will be helpful for the discovery of novel albomycin analogues or related compounds.</p></sec><sec id="sec6-antibiotics-11-00438"><title>6. Chemical Synthesis</title><p>Chemical synthesis of the tri-&#x003b4;-<italic toggle="yes">N</italic>-hydroxy-L-ornithine peptide siderophore was initially described by Benz and coworkers in 1984 [<xref rid="B51-antibiotics-11-00438" ref-type="bibr">51</xref>,<xref rid="B52-antibiotics-11-00438" ref-type="bibr">52</xref>]. Later, different synthetic strategies were described by Miller and coworkers in 1990s [<xref rid="B53-antibiotics-11-00438" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-11-00438" ref-type="bibr">54</xref>,<xref rid="B55-antibiotics-11-00438" ref-type="bibr">55</xref>]. The synthesis of the thionucleoside moiety of albomycin &#x003b4;<sub>1</sub> (<bold>13</bold>) was also reported by Holzapfel and coworkers [<xref rid="B56-antibiotics-11-00438" ref-type="bibr">56</xref>]. In one recent study, <bold>13</bold> and its isoleucyl and aspartyl analogues (<bold>13a</bold> and <bold>13b</bold>) were synthesized by Van Aerschot and coworkers [<xref rid="B57-antibiotics-11-00438" ref-type="bibr">57</xref>]. Of note is that an oxygen analog of albomycin &#x003b4;<sub>1</sub> (<bold>1d</bold>) was synthesized by Benz and coworkers [<xref rid="B58-antibiotics-11-00438" ref-type="bibr">58</xref>]. Surprisingly, the oxygen analog lost its antibacterial activity, suggesting that the sulfur atom is indispensable for the bioactivity of albomycins [<xref rid="B59-antibiotics-11-00438" ref-type="bibr">59</xref>]. Furthermore, two aryl-tetrazole containing albomycin analogues (<bold>15a</bold> and <bold>15b</bold>) were obtained by Van Aerschot and coworkers (<xref rid="antibiotics-11-00438-f003" ref-type="fig">Figure 3</xref>). The two analogues were synthesized by coupling of aryl-tetrazole-containing compounds <bold>14a</bold> (CB168) and <bold>14b</bold> (CB432) to the tri-&#x003b4;-<italic toggle="yes">N</italic>-hydroxy-L-ornithine peptide siderophore [<xref rid="B60-antibiotics-11-00438" ref-type="bibr">60</xref>]. CB168 and CB432 were synthesized by Cubist Pharmaceuticals as potent aaRS inhibitors. Both CB168 and CB432 contain an aryl-tetrazole in place of the adenine moiety, and connected through a two-carbon linker to ribose [<xref rid="B61-antibiotics-11-00438" ref-type="bibr">61</xref>]. The tri-&#x003b4;-<italic toggle="yes">N</italic>-hydroxy-L-ornithine peptide siderophore were prepared as described by Miller and coworkers [<xref rid="B53-antibiotics-11-00438" ref-type="bibr">53</xref>]. Antimicrobial activities were then tested against <italic toggle="yes">Staphylococcus aureus</italic> (ATCC 6538), <italic toggle="yes">Staphylococcus epidermidis</italic> RP62A (ATCC 35984), <italic toggle="yes">Pseudomonas aeruginosa</italic> PAO1, <italic toggle="yes">Sarcina lutea</italic> (ATCC 9341), and <italic toggle="yes">Candida albicans</italic> CO11. Only one of the compounds showed weak activity against <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">C. albicans</italic>, though both analogues showed good activity against IleRS in vitro [<xref rid="B60-antibiotics-11-00438" ref-type="bibr">60</xref>]. Total synthesis of the three natural albomycin congeners has been accomplished recently by He and coworkers [<xref rid="B59-antibiotics-11-00438" ref-type="bibr">59</xref>]. For illustration purposes, we here only show a simplified scheme of albomycins synthesis (<xref rid="antibiotics-11-00438-sch002" ref-type="fig">Scheme 2</xref>). The efficient synthesis of albomycins enables biological evaluations of these potent inhibitors against three Gram-positive bacteria (<italic toggle="yes">S. pneumoniae</italic> ATCC 49619, <italic toggle="yes">S. aureus</italic> USA 300 NRS 384, and <italic toggle="yes">Bacillus subtilis</italic> ATCC 6633) and three Gram-negative bacteria (<italic toggle="yes">E. coli</italic> BJ 5183, <italic toggle="yes">Neisseria gonorrhoeae</italic> ATCC 49226, and <italic toggle="yes">Salmonella typhi</italic>), as well as 27 clinical <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">S. aureus</italic> isolates (three of them are methicillin-resistant strains). The results revealed that C<sub>4</sub> substituent on the nucleobase in albomycin plays an essential role in their antibacterial activity. Importantly, the systematic SAR study suggested that albomycin &#x003b4;<sub>2</sub> is the most promising candidate for further clinical drug development. Of particular interest is that the potency of albomycin &#x003b4;<sub>2</sub> exceeds that of well-established antibiotics ciprofloxacin, vancomycin, and penicillin [<xref rid="B59-antibiotics-11-00438" ref-type="bibr">59</xref>]. Inspired by these studies, more previously inaccessible analogues can be synthesized and subjected to systematic SAR studies. These studies will substantially expand the repertoire of novel albomycins that will ultimately expedite the design and development of effective antimicrobial agents.</p></sec><sec id="sec7-antibiotics-11-00438"><title>7. Concluding Remarks</title><p>Aminoacyl-tRNA synthetases (aaRSs) catalyze the charging of tRNA with a cognate amino acid. They are indispensable for protein synthesis in all three kingdoms of life. Due to their important role in cellular viability, aaRSs have been recognized as suitable targets for the development of novel antimicrobial agents [<xref rid="B6-antibiotics-11-00438" ref-type="bibr">6</xref>]. At present, there are three aaRS inhibitors in clinical practice. Mupirocin is an inhibitor of bacterial isoleucyl-tRNA synthetase (IleRS). It is mainly used as an antibacterial agent for the treatment of infection caused by Gram-positive bacteria, including methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) [<xref rid="B62-antibiotics-11-00438" ref-type="bibr">62</xref>,<xref rid="B63-antibiotics-11-00438" ref-type="bibr">63</xref>]. Tavaborole is an inhibitor of fungal leucyl-tRNA synthetases (LeuRSs). It was approved by the US Food and Drug Administration (FDA) for the treatment of onychomycosis caused by <italic toggle="yes">Trichophyton</italic> species [<xref rid="B64-antibiotics-11-00438" ref-type="bibr">64</xref>,<xref rid="B65-antibiotics-11-00438" ref-type="bibr">65</xref>]. Halofuginone is an inhibitor of proline-tRNA synthetases (ProRSs). This drug was FDA approved for the treatment of apicomplexan parasite infections in chickens and scleroderma in humans [<xref rid="B66-antibiotics-11-00438" ref-type="bibr">66</xref>].</p><p>Albomycins utilize the &#x0201c;Trojan horse&#x0201d; strategy to enter target bacterial cells. Once inside the cell, albomycins will be hydrolyzed by host peptidases to release the thionucleoside SB-217452 warhead that targets bacterial SerRSs. Thus, albomycins exhibit potent antibacterial activities against many model bacteria and a number of clinical pathogens [<xref rid="B59-antibiotics-11-00438" ref-type="bibr">59</xref>]. Over the past several decades, a significant progress has been made on the mechanism of action, biosynthesis and immunity, and chemical synthesis of albomycins. Previous studies suggested that the biosynthetic pathway proceeds through multiple steps of unusual enzymatic reactions [<xref rid="B38-antibiotics-11-00438" ref-type="bibr">38</xref>,<xref rid="B39-antibiotics-11-00438" ref-type="bibr">39</xref>]. However, there are still many missing gaps in our understanding of the biosynthetic process. Therefore, further genetic and biochemical studies are needed to bridge these gaps. For example, further studies are needed to clarify the functions of AbmQ and AbmC in the amide bond formation. Moreover, further experimental evidence is also required for the formation of ferrichrome-type siderophore moiety. These studies will provide the basis for pathway engineering and combinatorial biosynthesis to create new albomycin analogues.</p><p>Natural products still hold out the best options for finding novel antimicrobial agents [<xref rid="B3-antibiotics-11-00438" ref-type="bibr">3</xref>]. Advances in omics and bioinformatics have accelerated the identification of gene clusters for antibiotics biosynthesis. In recent years, resistance-guided genome mining has been used successfully for the discovery of novel antimicrobial agents [<xref rid="B1-antibiotics-11-00438" ref-type="bibr">1</xref>,<xref rid="B2-antibiotics-11-00438" ref-type="bibr">2</xref>,<xref rid="B49-antibiotics-11-00438" ref-type="bibr">49</xref>,<xref rid="B50-antibiotics-11-00438" ref-type="bibr">50</xref>]. As mentioned above, <italic toggle="yes">abmK</italic> can serve as a good candidate to search for homologous genes in public databases. Analysis of <italic toggle="yes">abmK</italic> homologues and the neighboring genes will be helpful for high-throughput screening of gene clusters encoding novel albomycin analogues. This large-scale genome mining open up new opportunities for the discovery and development of antimicrobial drugs to address the growing global threat of antimicrobial resistance.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.W.: Writing, reviewing, and editing; Y.Z.: Writing, reviewing, and editing; L.L.: Reviewing, and editing; D.K.: Reviewing, and editing; G.N.: Conceptualization, writing original draft, reviewing, and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was supported in part by grants from the National Natural Science Foundation of China (No. 31870061), Chongqing Science and Technology Commission (No. cstccxljrc201904), and Southwest University (No. SWU117015).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-11-00438"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>G.</given-names></name>
</person-group><article-title>Genomics-driven natural product discovery in actinomycetes</article-title><source>Trends Biotechnol.</source><year>2018</year><volume>36</volume><fpage>238</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2017.10.009</pub-id><?supplied-pmid 29126570?><pub-id pub-id-type="pmid">29126570</pub-id></element-citation></ref><ref id="B2-antibiotics-11-00438"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
</person-group><article-title>Next-generation drug discovery to combat antimicrobial resistance</article-title><source>Trends Biochem. Sci.</source><year>2019</year><volume>44</volume><fpage>961</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2019.05.005</pub-id><?supplied-pmid 31256981?><pub-id pub-id-type="pmid">31256981</pub-id></element-citation></ref><ref id="B3-antibiotics-11-00438"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>D.J.</given-names></name>
<name><surname>Cragg</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019</article-title><source>J. Nat. Prod.</source><year>2020</year><volume>83</volume><fpage>770</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b01285</pub-id><?supplied-pmid 32162523?><pub-id pub-id-type="pmid">32162523</pub-id></element-citation></ref><ref id="B4-antibiotics-11-00438"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>B.</given-names></name>
</person-group><article-title>A new golden age of natural products drug discovery</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>1297</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.031</pub-id><pub-id pub-id-type="pmid">26638061</pub-id></element-citation></ref><ref id="B5-antibiotics-11-00438"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harvey</surname><given-names>A.L.</given-names></name>
<name><surname>Edrada-Ebel</surname><given-names>R.</given-names></name>
<name><surname>Quinn</surname><given-names>R.J.</given-names></name>
</person-group><article-title>The re-emergence of natural products for drug discovery in the genomics era</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>111</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/nrd4510</pub-id><pub-id pub-id-type="pmid">25614221</pub-id></element-citation></ref><ref id="B6-antibiotics-11-00438"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>L.</given-names></name>
<name><surname>Weeks</surname><given-names>S.D.</given-names></name>
<name><surname>Van Aerschot</surname><given-names>A.</given-names></name>
</person-group><article-title>Aminoacyl-tRNA synthetases as valuable targets for antimicrobial drug discovery</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>1750</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22041750</pub-id><pub-id pub-id-type="pmid">33578647</pub-id></element-citation></ref><ref id="B7-antibiotics-11-00438"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibba</surname><given-names>M.</given-names></name>
<name><surname>Soll</surname><given-names>D.</given-names></name>
</person-group><article-title>Aminoacyl-tRNA synthesis</article-title><source>Annu. Rev. Biochem.</source><year>2000</year><volume>69</volume><fpage>617</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.69.1.617</pub-id><pub-id pub-id-type="pmid">10966471</pub-id></element-citation></ref><ref id="B8-antibiotics-11-00438"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gorska</surname><given-names>A.</given-names></name>
<name><surname>Sloderbach</surname><given-names>A.</given-names></name>
<name><surname>Marszall</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Siderophore-drug complexes: Potential medicinal applications of the &#x02018;Trojan horse&#x02019; strategy</article-title><source>Trends Pharmacol. Sci.</source><year>2014</year><volume>35</volume><fpage>442</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.06.007</pub-id><pub-id pub-id-type="pmid">25108321</pub-id></element-citation></ref><ref id="B9-antibiotics-11-00438"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Braun</surname><given-names>V.</given-names></name>
<name><surname>Pramanik</surname><given-names>A.</given-names></name>
<name><surname>Gwinner</surname><given-names>T.</given-names></name>
<name><surname>Koberle</surname><given-names>M.</given-names></name>
<name><surname>Bohn</surname><given-names>E.</given-names></name>
</person-group><article-title>Sideromycins: Tools and antibiotics</article-title><source>Biometals</source><year>2009</year><volume>22</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s10534-008-9199-7</pub-id><pub-id pub-id-type="pmid">19130258</pub-id></element-citation></ref><ref id="B10-antibiotics-11-00438"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Travin</surname><given-names>D.Y.</given-names></name>
<name><surname>Severinov</surname><given-names>K.</given-names></name>
<name><surname>Dubiley</surname><given-names>S.</given-names></name>
</person-group><article-title>Natural Trojan horse inhibitors of aminoacyl-tRNA synthetases</article-title><source>RSC Chem. Biol.</source><year>2021</year><volume>2</volume><fpage>468</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1039/D0CB00208A</pub-id><pub-id pub-id-type="pmid">34382000</pub-id></element-citation></ref><ref id="B11-antibiotics-11-00438"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vondenhoff</surname><given-names>G.H.</given-names></name>
<name><surname>Van Aerschot</surname><given-names>A.</given-names></name>
</person-group><article-title>Microcin C: Biosynthesis, mode of action, and potential as a lead in antibiotics development</article-title><source>Nucleosides Nucleotides Nucleic. Acids</source><year>2011</year><volume>30</volume><fpage>465</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1080/15257770.2011.583972</pub-id><?supplied-pmid 21888539?><pub-id pub-id-type="pmid">21888539</pub-id></element-citation></ref><ref id="B12-antibiotics-11-00438"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.G.</given-names></name>
<name><surname>Park</surname><given-names>B.K.</given-names></name>
<name><surname>Kim</surname><given-names>S.U.</given-names></name>
<name><surname>Choi</surname><given-names>D.</given-names></name>
<name><surname>Nahm</surname><given-names>B.H.</given-names></name>
<name><surname>Moon</surname><given-names>J.S.</given-names></name>
<name><surname>Reader</surname><given-names>J.S.</given-names></name>
<name><surname>Farrand</surname><given-names>S.K.</given-names></name>
<name><surname>Hwang</surname><given-names>I.</given-names></name>
</person-group><article-title>Bases of biocontrol: Sequence predicts synthesis and mode of action of agrocin 84, the Trojan horse antibiotic that controls crown gall</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>8846</fpage><lpage>8851</lpage><pub-id pub-id-type="doi">10.1073/pnas.0602965103</pub-id><?supplied-pmid 16731618?><pub-id pub-id-type="pmid">16731618</pub-id></element-citation></ref><ref id="B13-antibiotics-11-00438"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chopra</surname><given-names>S.</given-names></name>
<name><surname>Palencia</surname><given-names>A.</given-names></name>
<name><surname>Virus</surname><given-names>C.</given-names></name>
<name><surname>Schulwitz</surname><given-names>S.</given-names></name>
<name><surname>Temple</surname><given-names>B.R.</given-names></name>
<name><surname>Cusack</surname><given-names>S.</given-names></name>
<name><surname>Reader</surname><given-names>J.</given-names></name>
</person-group><article-title>Structural characterization of antibiotic self-immunity tRNA synthetase in plant tumour biocontrol agent</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>12928</fpage><pub-id pub-id-type="doi">10.1038/ncomms12928</pub-id><?supplied-pmid 27713402?><pub-id pub-id-type="pmid">27713402</pub-id></element-citation></ref><ref id="B14-antibiotics-11-00438"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>D.M.</given-names></name>
<name><surname>Schatz</surname><given-names>A.</given-names></name>
<name><surname>Waksman</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Grisein, a new antibiotic produced by a strain of <italic toggle="yes">Streptomyces griseus</italic></article-title><source>Proc. Soc. Exp. Biol. Med.</source><year>1947</year><volume>64</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.3181/00379727-64-15695</pub-id><pub-id pub-id-type="pmid">20285459</pub-id></element-citation></ref><ref id="B15-antibiotics-11-00438"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>D.M.</given-names></name>
<name><surname>Waksman</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Grisein, an antibiotic produced by certain strains of <italic toggle="yes">Streptomyces griseus</italic></article-title><source>J. Bacteriol.</source><year>1948</year><volume>55</volume><fpage>739</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1128/jb.55.5.739-752.1948</pub-id><?supplied-pmid 16561513?><pub-id pub-id-type="pmid">16561513</pub-id></element-citation></ref><ref id="B16-antibiotics-11-00438"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gause</surname><given-names>G.F.</given-names></name>
</person-group><article-title>Recent studies on albomycin, a new antibiotic</article-title><source>Br. Med. J.</source><year>1955</year><volume>2</volume><fpage>1177</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1136/bmj.2.4949.1177</pub-id><pub-id pub-id-type="pmid">13269824</pub-id></element-citation></ref><ref id="B17-antibiotics-11-00438"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stapley</surname><given-names>E.O.</given-names></name>
<name><surname>Ormond</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Similarity of albomycin and grisein</article-title><source>Science</source><year>1957</year><volume>125</volume><fpage>587</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1126/science.125.3248.587</pub-id><pub-id pub-id-type="pmid">13409012</pub-id></element-citation></ref><ref id="B18-antibiotics-11-00438"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maehr</surname><given-names>H.</given-names></name>
<name><surname>Pitcher</surname><given-names>R.G.</given-names></name>
</person-group><article-title>Identity of albomycin &#x003b4;<sub>2</sub> and antibiotic Ro 5-2667</article-title><source>J. Antibiot.</source><year>1971</year><volume>24</volume><fpage>830</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.24.830</pub-id></element-citation></ref><ref id="B19-antibiotics-11-00438"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maehr</surname><given-names>H.</given-names></name>
</person-group><article-title>Antibiotics and other naturally occurring hydroxamic acids and hydroxamates</article-title><source>Pure Appl. Chem.</source><year>1971</year><volume>28</volume><fpage>603</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1351/pac197128040603</pub-id><pub-id pub-id-type="pmid">5004169</pub-id></element-citation></ref><ref id="B20-antibiotics-11-00438"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benz</surname><given-names>G.</given-names></name>
<name><surname>Schr&#x000f6;der</surname><given-names>T.</given-names></name>
<name><surname>Kurz</surname><given-names>J.</given-names></name>
<name><surname>W&#x000fc;nsche</surname><given-names>C.</given-names></name>
<name><surname>Karl</surname><given-names>W.</given-names></name>
<name><surname>Steffens</surname><given-names>G.</given-names></name>
<name><surname>Pfitzner</surname><given-names>J.</given-names></name>
<name><surname>Schmidt</surname><given-names>D.</given-names></name>
</person-group><article-title>Constitution of the deferriform of the albomycins &#x003b4;<sub>1</sub>, &#x003b4;<sub>2</sub> and &#x003b5;</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>1982</year><volume>21</volume><fpage>527</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1002/anie.198205271</pub-id></element-citation></ref><ref id="B21-antibiotics-11-00438"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benz</surname><given-names>G.</given-names></name>
<name><surname>Schr&#x000f6;der</surname><given-names>T.</given-names></name>
<name><surname>Kurz</surname><given-names>J.</given-names></name>
<name><surname>W&#x000fc;nsche</surname><given-names>C.</given-names></name>
<name><surname>Karl</surname><given-names>W.</given-names></name>
<name><surname>Steffens</surname><given-names>G.</given-names></name>
<name><surname>Pfitzner</surname><given-names>J.</given-names></name>
<name><surname>Schmidt</surname><given-names>D.</given-names></name>
</person-group><article-title>Konstitution der Desferriform der Albomycine &#x003b4;1, &#x003b4;2, &#x003b5;</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>1982</year><volume>21</volume><fpage>1322</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1002/anie.198213220</pub-id></element-citation></ref><ref id="B22-antibiotics-11-00438"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haas</surname><given-names>H.</given-names></name>
</person-group><article-title>Fungal siderophore metabolism with a focus on <italic toggle="yes">Aspergillus fumigatus</italic></article-title><source>Nat. Prod. Rep.</source><year>2014</year><volume>31</volume><fpage>1266</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1039/C4NP00071D</pub-id><?supplied-pmid 25140791?><pub-id pub-id-type="pmid">25140791</pub-id></element-citation></ref><ref id="B23-antibiotics-11-00438"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asai</surname><given-names>Y.</given-names></name>
<name><surname>Hiratsuka</surname><given-names>T.</given-names></name>
<name><surname>Ueda</surname><given-names>M.</given-names></name>
<name><surname>Kawamura</surname><given-names>Y.</given-names></name>
<name><surname>Asamizu</surname><given-names>S.</given-names></name>
<name><surname>Onaka</surname><given-names>H.</given-names></name>
<name><surname>Arioka</surname><given-names>M.</given-names></name>
<name><surname>Nishimura</surname><given-names>S.</given-names></name>
<name><surname>Yoshida</surname><given-names>M.</given-names></name>
</person-group><article-title>Differential biosynthesis and roles of two ferrichrome-type siderophores, ASP2397/AS2488053 and ferricrocin, in <italic toggle="yes">Acremonium persicinum</italic></article-title><source>ACS Chem. Biol.</source><year>2022</year><volume>17</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1021/acschembio.1c00867</pub-id><?supplied-pmid 35000376?><pub-id pub-id-type="pmid">35000376</pub-id></element-citation></ref><ref id="B24-antibiotics-11-00438"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>G.</given-names></name>
<name><surname>Tan</surname><given-names>H.</given-names></name>
</person-group><article-title>Nucleoside antibiotics: Biosynthesis, regulation, and biotechnology</article-title><source>Trends Microbiol.</source><year>2015</year><volume>23</volume><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2014.10.007</pub-id><pub-id pub-id-type="pmid">25468791</pub-id></element-citation></ref><ref id="B25-antibiotics-11-00438"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shiraishi</surname><given-names>T.</given-names></name>
<name><surname>Kuzuyama</surname><given-names>T.</given-names></name>
</person-group><article-title>Recent advances in the biosynthesis of nucleoside antibiotics</article-title><source>J. Antibiot.</source><year>2019</year><volume>72</volume><fpage>913</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1038/s41429-019-0236-2</pub-id></element-citation></ref><ref id="B26-antibiotics-11-00438"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pramanik</surname><given-names>A.</given-names></name>
<name><surname>Stroeher</surname><given-names>U.H.</given-names></name>
<name><surname>Krejci</surname><given-names>J.</given-names></name>
<name><surname>Standish</surname><given-names>A.J.</given-names></name>
<name><surname>Bohn</surname><given-names>E.</given-names></name>
<name><surname>Paton</surname><given-names>J.C.</given-names></name>
<name><surname>Autenrieth</surname><given-names>I.B.</given-names></name>
<name><surname>Braun</surname><given-names>V.</given-names></name>
</person-group><article-title>Albomycin is an effective antibiotic, as exemplified with <italic toggle="yes">Yersinia enterocolitica</italic> and <italic toggle="yes">Streptococcus pneumoniae</italic></article-title><source>Int. J. Med. Microbiol.</source><year>2007</year><volume>297</volume><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2007.03.002</pub-id><pub-id pub-id-type="pmid">17459767</pub-id></element-citation></ref><ref id="B27-antibiotics-11-00438"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pramanik</surname><given-names>A.</given-names></name>
<name><surname>Braun</surname><given-names>V.</given-names></name>
</person-group><article-title>Albomycin uptake via a ferric hydroxamate transport system of <italic toggle="yes">Streptococcus pneumoniae</italic> R6</article-title><source>J. Bacteriol.</source><year>2006</year><volume>188</volume><fpage>3878</fpage><lpage>3886</lpage><pub-id pub-id-type="doi">10.1128/JB.00205-06</pub-id><pub-id pub-id-type="pmid">16707680</pub-id></element-citation></ref><ref id="B28-antibiotics-11-00438"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al Shaer</surname><given-names>D.</given-names></name>
<name><surname>Al Musaimi</surname><given-names>O.</given-names></name>
<name><surname>de la Torre</surname><given-names>B.G.</given-names></name>
<name><surname>Albericio</surname><given-names>F.</given-names></name>
</person-group><article-title>Hydroxamate siderophores: Natural occurrence, chemical synthesis, iron binding affinity and use as Trojan horses against pathogens</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>208</volume><fpage>112791</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112791</pub-id><pub-id pub-id-type="pmid">32947228</pub-id></element-citation></ref><ref id="B29-antibiotics-11-00438"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neilands</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Microbial envelope proteins related to iron</article-title><source>Annu. Rev. Microbiol.</source><year>1982</year><volume>36</volume><fpage>285</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1146/annurev.mi.36.100182.001441</pub-id><pub-id pub-id-type="pmid">6293371</pub-id></element-citation></ref><ref id="B30-antibiotics-11-00438"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Braun</surname><given-names>V.</given-names></name>
</person-group><article-title>Active transport of siderophore-mimicking antibacterials across the outer membrane</article-title><source>Drug Resist. Update</source><year>1999</year><volume>2</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1054/drup.1999.0107</pub-id></element-citation></ref><ref id="B31-antibiotics-11-00438"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferguson</surname><given-names>A.D.</given-names></name>
<name><surname>Braun</surname><given-names>V.</given-names></name>
<name><surname>Fiedler</surname><given-names>H.P.</given-names></name>
<name><surname>Coulton</surname><given-names>J.W.</given-names></name>
<name><surname>Diederichs</surname><given-names>K.</given-names></name>
<name><surname>Welte</surname><given-names>W.</given-names></name>
</person-group><article-title>Crystal structure of the antibiotic albomycin in complex with the outer membrane transporter FhuA</article-title><source>Protein Sci.</source><year>2000</year><volume>9</volume><fpage>956</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1110/ps.9.5.956</pub-id><?supplied-pmid 10850805?><pub-id pub-id-type="pmid">10850805</pub-id></element-citation></ref><ref id="B32-antibiotics-11-00438"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Killmann</surname><given-names>H.</given-names></name>
<name><surname>Herrmann</surname><given-names>C.</given-names></name>
<name><surname>Torun</surname><given-names>A.</given-names></name>
<name><surname>Jung</surname><given-names>G.</given-names></name>
<name><surname>Braun</surname><given-names>V.</given-names></name>
</person-group><article-title>TonB of <italic toggle="yes">Escherichia coli</italic> activates FhuA through interaction with the &#x003b2;-barrel</article-title><source>Microbiology</source><year>2002</year><volume>148</volume><fpage>3497</fpage><lpage>3509</lpage><pub-id pub-id-type="doi">10.1099/00221287-148-11-3497</pub-id><?supplied-pmid 12427941?><pub-id pub-id-type="pmid">12427941</pub-id></element-citation></ref><ref id="B33-antibiotics-11-00438"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rohrbach</surname><given-names>M.R.</given-names></name>
<name><surname>Braun</surname><given-names>V.</given-names></name>
<name><surname>Koster</surname><given-names>W.</given-names></name>
</person-group><article-title>Ferrichrome transport in <italic toggle="yes">Escherichia coli</italic> K-12: Altered substrate specificity of mutated periplasmic FhuD and interaction of FhuD with the integral membrane protein FhuB</article-title><source>J. Bacteriol.</source><year>1995</year><volume>177</volume><fpage>7186</fpage><lpage>7193</lpage><pub-id pub-id-type="doi">10.1128/jb.177.24.7186-7193.1995</pub-id><?supplied-pmid 8522527?><pub-id pub-id-type="pmid">8522527</pub-id></element-citation></ref><ref id="B34-antibiotics-11-00438"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schultz-Hauser</surname><given-names>G.</given-names></name>
<name><surname>Koster</surname><given-names>W.</given-names></name>
<name><surname>Schwarz</surname><given-names>H.</given-names></name>
<name><surname>Braun</surname><given-names>V.</given-names></name>
</person-group><article-title>Iron (III) hydroxamate transport in <italic toggle="yes">Escherichia coli</italic> K-12: FhuB-mediated membrane association of the FhuC protein and negative complementation of <italic toggle="yes">fhuC</italic> mutants</article-title><source>J. Bacteriol.</source><year>1992</year><volume>174</volume><fpage>2305</fpage><lpage>2311</lpage><pub-id pub-id-type="doi">10.1128/jb.174.7.2305-2311.1992</pub-id><pub-id pub-id-type="pmid">1551849</pub-id></element-citation></ref><ref id="B35-antibiotics-11-00438"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kadner</surname><given-names>R.J.</given-names></name>
<name><surname>Heller</surname><given-names>K.</given-names></name>
<name><surname>Coulton</surname><given-names>J.W.</given-names></name>
<name><surname>Braun</surname><given-names>V.</given-names></name>
</person-group><article-title>Genetic control of hydroxamate-mediated iron uptake in <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Bacteriol.</source><year>1980</year><volume>143</volume><fpage>256</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1128/jb.143.1.256-264.1980</pub-id><pub-id pub-id-type="pmid">6249788</pub-id></element-citation></ref><ref id="B36-antibiotics-11-00438"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Braun</surname><given-names>V.</given-names></name>
<name><surname>Gunthner</surname><given-names>K.</given-names></name>
<name><surname>Hantke</surname><given-names>K.</given-names></name>
<name><surname>Zimmermann</surname><given-names>L.</given-names></name>
</person-group><article-title>Intracellular activation of albomycin in <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Salmonella typhimurium</italic></article-title><source>J. Bacteriol.</source><year>1983</year><volume>156</volume><fpage>308</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1128/jb.156.1.308-315.1983</pub-id><pub-id pub-id-type="pmid">6352681</pub-id></element-citation></ref><ref id="B37-antibiotics-11-00438"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>Y.</given-names></name>
<name><surname>Kulkarni</surname><given-names>A.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Patil</surname><given-names>P.B.</given-names></name>
<name><surname>Zhou</surname><given-names>W.</given-names></name>
<name><surname>Chi</surname><given-names>X.</given-names></name>
<name><surname>Van Lanen</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
</person-group><article-title>Biosynthesis of albomycin &#x003b4;<sub>2</sub> provides a template for assembling siderophore and aminoacyl-tRNA synthetase inhibitor conjugates</article-title><source>ACS Chem. Biol.</source><year>2012</year><volume>7</volume><fpage>1565</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1021/cb300173x</pub-id><pub-id pub-id-type="pmid">22704654</pub-id></element-citation></ref><ref id="B38-antibiotics-11-00438"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ushimaru</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Biosynthetic origin of the atypical stereochemistry in the thioheptose core of albomycin nucleoside antibiotics</article-title><source>J. Am. Chem. Soc.</source><year>2019</year><volume>141</volume><fpage>2211</fpage><lpage>2214</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b12565</pub-id><pub-id pub-id-type="pmid">30673214</pub-id></element-citation></ref><ref id="B39-antibiotics-11-00438"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ushimaru</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>P.H.</given-names></name>
<name><surname>Liu</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Identification of the enzymes mediating the maturation of the Seryl-tRNA synthetase inhibitor SB-217452 during the biosynthesis of albomycins</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2020</year><volume>59</volume><fpage>3558</fpage><lpage>3562</lpage><pub-id pub-id-type="doi">10.1002/anie.201915275</pub-id><pub-id pub-id-type="pmid">31863717</pub-id></element-citation></ref><ref id="B40-antibiotics-11-00438"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garg</surname><given-names>R.P.</given-names></name>
<name><surname>Gonzalez</surname><given-names>J.M.</given-names></name>
<name><surname>Parry</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Biochemical characterization of VlmL, a Seryl-tRNA synthetase encoded by the valanimycin biosynthetic gene cluster</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>26785</fpage><lpage>26791</lpage><pub-id pub-id-type="doi">10.1074/jbc.M603675200</pub-id><pub-id pub-id-type="pmid">16857674</pub-id></element-citation></ref><ref id="B41-antibiotics-11-00438"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garg</surname><given-names>R.P.</given-names></name>
<name><surname>Qian</surname><given-names>X.L.</given-names></name>
<name><surname>Alemany</surname><given-names>L.B.</given-names></name>
<name><surname>Moran</surname><given-names>S.</given-names></name>
<name><surname>Parry</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Investigations of valanimycin biosynthesis: Elucidation of the role of seryl-tRNA</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>6543</fpage><lpage>6547</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708957105</pub-id><?supplied-pmid 18451033?><pub-id pub-id-type="pmid">18451033</pub-id></element-citation></ref><ref id="B42-antibiotics-11-00438"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mullowney</surname><given-names>M.W.</given-names></name>
<name><surname>McClure</surname><given-names>R.A.</given-names></name>
<name><surname>Robey</surname><given-names>M.T.</given-names></name>
<name><surname>Kelleher</surname><given-names>N.L.</given-names></name>
<name><surname>Thomson</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Natural products from thioester reductase containing biosynthetic pathways</article-title><source>Nat. Prod. Rep.</source><year>2018</year><volume>35</volume><fpage>847</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1039/C8NP00013A</pub-id><?supplied-pmid 29916519?><pub-id pub-id-type="pmid">29916519</pub-id></element-citation></ref><ref id="B43-antibiotics-11-00438"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mo&#x0010d;ibob</surname><given-names>M.</given-names></name>
<name><surname>Rokov-Plavec</surname><given-names>J.</given-names></name>
<name><surname>Godinic-Mikulcic</surname><given-names>V.</given-names></name>
<name><surname>Gruic-Sovulj</surname><given-names>I.</given-names></name>
</person-group><article-title>Seryl-tRNA synthetases in translation and beyond</article-title><source>Croat. Chem. Acta</source><year>2016</year><volume>89</volume><fpage>261</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.5562/cca2908</pub-id></element-citation></ref><ref id="B44-antibiotics-11-00438"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>Y.</given-names></name>
<name><surname>Roy</surname><given-names>H.</given-names></name>
<name><surname>Patil</surname><given-names>P.B.</given-names></name>
<name><surname>Ibba</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
</person-group><article-title>Characterization of two seryl-tRNA synthetases in albomycin-producing <italic toggle="yes">Streptomyces</italic> sp. strain ATCC 700974</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>4619</fpage><lpage>4627</lpage><pub-id pub-id-type="doi">10.1128/AAC.00782-09</pub-id><pub-id pub-id-type="pmid">19721072</pub-id></element-citation></ref><ref id="B45-antibiotics-11-00438"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yanagisawa</surname><given-names>T.</given-names></name>
<name><surname>Kawakami</surname><given-names>M.</given-names></name>
</person-group><article-title>How does <italic toggle="yes">Pseudomonas fluorescens</italic> avoid suicide from its antibiotic pseudomonic acid?: Evidence for two evolutionarily distinct isoleucyl-tRNA synthetases conferring self-defense</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>25887</fpage><lpage>25894</lpage><pub-id pub-id-type="doi">10.1074/jbc.M302633200</pub-id><pub-id pub-id-type="pmid">12672810</pub-id></element-citation></ref><ref id="B46-antibiotics-11-00438"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olano</surname><given-names>C.</given-names></name>
<name><surname>Wilkinson</surname><given-names>B.</given-names></name>
<name><surname>Sanchez</surname><given-names>C.</given-names></name>
<name><surname>Moss</surname><given-names>S.J.</given-names></name>
<name><surname>Sheridan</surname><given-names>R.</given-names></name>
<name><surname>Math</surname><given-names>V.</given-names></name>
<name><surname>Weston</surname><given-names>A.J.</given-names></name>
<name><surname>Brana</surname><given-names>A.F.</given-names></name>
<name><surname>Martin</surname><given-names>C.J.</given-names></name>
<name><surname>Oliynyk</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Biosynthesis of the angiogenesis inhibitor borrelidin by <italic toggle="yes">Streptomyces parvulus</italic> Tu4055: Cluster analysis and assignment of functions</article-title><source>Chem. Biol.</source><year>2004</year><volume>11</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">15112998</pub-id></element-citation></ref><ref id="B47-antibiotics-11-00438"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vecchione</surname><given-names>J.J.</given-names></name>
<name><surname>Sello</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Characterization of an inducible, antibiotic-resistant aminoacyl-tRNA synthetase gene in <italic toggle="yes">Streptomyces coelicolor</italic></article-title><source>J. Bacteriol.</source><year>2008</year><volume>190</volume><fpage>6253</fpage><lpage>6257</lpage><pub-id pub-id-type="doi">10.1128/JB.00737-08</pub-id><pub-id pub-id-type="pmid">18621902</pub-id></element-citation></ref><ref id="B48-antibiotics-11-00438"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitabatake</surname><given-names>M.</given-names></name>
<name><surname>Ali</surname><given-names>K.</given-names></name>
<name><surname>Demain</surname><given-names>A.</given-names></name>
<name><surname>Sakamoto</surname><given-names>K.</given-names></name>
<name><surname>Yokoyama</surname><given-names>S.</given-names></name>
<name><surname>Soll</surname><given-names>D.</given-names></name>
</person-group><article-title>Indolmycin resistance of <italic toggle="yes">Streptomyces coelicolor</italic> A3(2) by induced expression of one of its two tryptophanyl-tRNA synthetases</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>23882</fpage><lpage>23887</lpage><pub-id pub-id-type="doi">10.1074/jbc.M202639200</pub-id><pub-id pub-id-type="pmid">11970956</pub-id></element-citation></ref><ref id="B49-antibiotics-11-00438"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>N.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Recent developments in self-resistance gene directed natural product discovery</article-title><source>Nat. Prod. Rep.</source><year>2020</year><volume>37</volume><fpage>879</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1039/C9NP00050J</pub-id><pub-id pub-id-type="pmid">31912842</pub-id></element-citation></ref><ref id="B50-antibiotics-11-00438"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flemming</surname><given-names>A.</given-names></name>
</person-group><article-title>Antibacterials: Resistance-guided discovery of new antibiotics</article-title><source>Nat. Rev. Drug Discov.</source><year>2013</year><volume>12</volume><fpage>826</fpage><pub-id pub-id-type="doi">10.1038/nrd4158</pub-id></element-citation></ref><ref id="B51-antibiotics-11-00438"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benz</surname><given-names>G.</given-names></name>
<name><surname>Schmidt</surname><given-names>D.</given-names></name>
</person-group><article-title>Albomycine, IV. Isolierung und totalsynthese von (<italic toggle="yes">N<sup>5</sup></italic>-acetyl-<italic toggle="yes">N<sup>5</sup></italic>-hydroxy-L-ornithyl)-(<italic toggle="yes">N<sup>5</sup></italic>-acetyl-<italic toggle="yes">N<sup>5</sup></italic>-hydroxy-L-ornithyl)-<italic toggle="yes">N<sup>5</sup></italic>-acetyl-<italic toggle="yes">N<sup>5</sup></italic>-hydroxy-L-ornithin</article-title><source>Liebigs Ann. Chem.</source><year>1984</year><volume>1984</volume><fpage>1434</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1002/jlac.198419840805</pub-id></element-citation></ref><ref id="B52-antibiotics-11-00438"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benz</surname><given-names>G.</given-names></name>
</person-group><article-title>Albomycins, III. Synthesis of <italic toggle="yes">N<sup>5</sup></italic>-acetyl-<italic toggle="yes">N<sup>5</sup></italic>-hydroxy-L-ornithine from L-glutamic acid</article-title><source>Liebigs Ann. Chem.</source><year>1984</year><volume>8</volume><fpage>1424</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1002/jlac.198419840804</pub-id></element-citation></ref><ref id="B53-antibiotics-11-00438"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Y.-M.</given-names></name>
<name><surname>Miller</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Practical synthesis of hydroxamate-derived siderophore components by an indirect oxidation method and syntheses of a DIG&#x02212;siderophore conjugate and a biotin&#x02212;siderophore conjugate</article-title><source>J. Org. Chem.</source><year>1999</year><volume>64</volume><fpage>7451</fpage><lpage>7458</lpage><pub-id pub-id-type="doi">10.1021/jo990769y</pub-id></element-citation></ref><ref id="B54-antibiotics-11-00438"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dolence</surname><given-names>E.K.</given-names></name>
<name><surname>Lin</surname><given-names>C.E.</given-names></name>
<name><surname>Miller</surname><given-names>M.J.</given-names></name>
<name><surname>Payne</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Synthesis and siderophore activity of albomycin-like peptides derived from <italic toggle="yes">N<sup>5</sup></italic>-acetyl-<italic toggle="yes">N<sup>5</sup></italic>-hydroxy-L-ornithine</article-title><source>J. Med. Chem.</source><year>1991</year><volume>34</volume><fpage>956</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1021/jm00107a013</pub-id><pub-id pub-id-type="pmid">1825849</pub-id></element-citation></ref><ref id="B55-antibiotics-11-00438"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dolence</surname><given-names>E.K.</given-names></name>
<name><surname>Minnick</surname><given-names>A.A.</given-names></name>
<name><surname>Miller</surname><given-names>M.J.</given-names></name>
</person-group><article-title><italic toggle="yes">N<sup>5</sup></italic>-acetyl-<italic toggle="yes">N<sup>5</sup></italic>-hydroxy-L-ornithine-derived siderophore-carbacephalosporin beta-lactam conjugates: Iron transport mediated drug delivery</article-title><source>J. Med. Chem.</source><year>1990</year><volume>33</volume><fpage>461</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1021/jm00164a001</pub-id><pub-id pub-id-type="pmid">2137180</pub-id></element-citation></ref><ref id="B56-antibiotics-11-00438"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bredenkamp</surname><given-names>A.D.</given-names></name>
<name><surname>Martin</surname><given-names>W.</given-names></name>
<name><surname>Holzapfel</surname><given-names>C.W.</given-names></name>
<name><surname>Swanepoel</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Synthesis of the thionucleoside moiety of albomycin &#x003b4;<sub>1</sub></article-title><source>S. Afr. Chem.</source><year>1991</year><volume>44</volume><fpage>31</fpage><lpage>33</lpage></element-citation></ref><ref id="B57-antibiotics-11-00438"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gadakh</surname><given-names>B.</given-names></name>
<name><surname>Vondenhoff</surname><given-names>G.</given-names></name>
<name><surname>Pang</surname><given-names>L.</given-names></name>
<name><surname>Nautiyal</surname><given-names>M.</given-names></name>
<name><surname>De Graef</surname><given-names>S.</given-names></name>
<name><surname>Strelkov</surname><given-names>S.V.</given-names></name>
<name><surname>Weeks</surname><given-names>S.D.</given-names></name>
<name><surname>Van Aerschot</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis and structural insights into the binding mode of the albomycin &#x003b4;<sub>1</sub> core and its analogues in complex with their target aminoacyl-tRNA synthetase</article-title><source>Bioorg. Med. Chem.</source><year>2020</year><volume>28</volume><fpage>115645</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2020.115645</pub-id><pub-id pub-id-type="pmid">32773091</pub-id></element-citation></ref><ref id="B58-antibiotics-11-00438"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paulsen</surname><given-names>H.</given-names></name>
<name><surname>Brieden</surname><given-names>M.</given-names></name>
<name><surname>Benz</surname><given-names>G.</given-names></name>
</person-group><article-title>Verzweigte und kettenverl&#x000e4;ngerte Zucker, XXXI. Synthese des Sauerstoffanalogons der Desferriform von &#x003b4;<sub>1</sub>-Albomycin</article-title><source>Liebigs Ann. Chem.</source><year>1987</year><volume>1987</volume><fpage>565</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1002/jlac.198719870702</pub-id></element-citation></ref><ref id="B59-antibiotics-11-00438"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Jing</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
</person-group><article-title>Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3445</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05821-1</pub-id><pub-id pub-id-type="pmid">30181560</pub-id></element-citation></ref><ref id="B60-antibiotics-11-00438"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vondenhoff</surname><given-names>G.H.</given-names></name>
<name><surname>Gadakh</surname><given-names>B.</given-names></name>
<name><surname>Severinov</surname><given-names>K.</given-names></name>
<name><surname>Van Aerschot</surname><given-names>A.</given-names></name>
</person-group><article-title>Microcin C and albomycin analogues with aryl-tetrazole substituents as nucleobase isosters are selective inhibitors of bacterial aminoacyl tRNA synthetases but lack efficient uptake</article-title><source>Chembiochem</source><year>2012</year><volume>13</volume><fpage>1959</fpage><lpage>1969</lpage><pub-id pub-id-type="doi">10.1002/cbic.201200174</pub-id><pub-id pub-id-type="pmid">22847961</pub-id></element-citation></ref><ref id="B61-antibiotics-11-00438"><label>61.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Hill</surname><given-names>J.M.</given-names></name>
<name><surname>Yu</surname><given-names>G.</given-names></name>
<name><surname>Shue</surname><given-names>Y.K.</given-names></name>
<name><surname>Zydowsky</surname><given-names>T.M.</given-names></name>
<name><surname>Rebek</surname><given-names>J.</given-names></name>
</person-group><article-title>Aminoacyl Adenylate Mimics as Novel Antimicrobial and Antiparasitic Agents</article-title><source>U.S. Patent</source><patent>5,726,195</patent><day>10</day><month>March</month><year>1998</year></element-citation></ref><ref id="B62-antibiotics-11-00438"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khoshnood</surname><given-names>S.</given-names></name>
<name><surname>Heidary</surname><given-names>M.</given-names></name>
<name><surname>Asadi</surname><given-names>A.</given-names></name>
<name><surname>Soleimani</surname><given-names>S.</given-names></name>
<name><surname>Motahar</surname><given-names>M.</given-names></name>
<name><surname>Savari</surname><given-names>M.</given-names></name>
<name><surname>Saki</surname><given-names>M.</given-names></name>
<name><surname>Abdi</surname><given-names>M.</given-names></name>
</person-group><article-title>A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>109</volume><fpage>1809</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.10.131</pub-id><?supplied-pmid 30551435?><pub-id pub-id-type="pmid">30551435</pub-id></element-citation></ref><ref id="B63-antibiotics-11-00438"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tucaliuc</surname><given-names>A.</given-names></name>
<name><surname>Blaga</surname><given-names>A.C.</given-names></name>
<name><surname>Galaction</surname><given-names>A.I.</given-names></name>
<name><surname>Cascaval</surname><given-names>D.</given-names></name>
</person-group><article-title>Mupirocin: Applications and production</article-title><source>Biotechnol. Lett.</source><year>2019</year><volume>41</volume><fpage>495</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1007/s10529-019-02670-w</pub-id><?supplied-pmid 30927135?><pub-id pub-id-type="pmid">30927135</pub-id></element-citation></ref><ref id="B64-antibiotics-11-00438"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barak</surname><given-names>O.</given-names></name>
<name><surname>Loo</surname><given-names>D.S.</given-names></name>
</person-group><article-title>AN-2690, a novel antifungal for the topical treatment of onychomycosis</article-title><source>Curr. Opin. Investig. Drugs</source><year>2007</year><volume>8</volume><fpage>662</fpage><lpage>668</lpage><?supplied-pmid 17668368?><pub-id pub-id-type="pmid">17668368</pub-id></element-citation></ref><ref id="B65-antibiotics-11-00438"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coghi</surname><given-names>P.S.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Hosmane</surname><given-names>N.S.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Organoboron compounds: Effective antibacterial and antiparasitic agents</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>3309</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26113309</pub-id><?supplied-pmid 34072937?><pub-id pub-id-type="pmid">34072937</pub-id></element-citation></ref><ref id="B66-antibiotics-11-00438"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pines</surname><given-names>M.</given-names></name>
<name><surname>Snyder</surname><given-names>D.</given-names></name>
<name><surname>Yarkoni</surname><given-names>S.</given-names></name>
<name><surname>Nagler</surname><given-names>A.</given-names></name>
</person-group><article-title>Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma</article-title><source>Biol. Blood Marrow Transplant.</source><year>2003</year><volume>9</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/S1083-8791(03)00151-4</pub-id><pub-id pub-id-type="pmid">12869955</pub-id></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Schemes</title><fig position="float" id="antibiotics-11-00438-sch001"><object-id pub-id-type="pii">antibiotics-11-00438-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>The two-step aminoacylation of tRNA catalyzed by aminoacyl-tRNA synthetases.</p></caption><graphic xlink:href="antibiotics-11-00438-sch001" position="float"/></fig><fig position="float" id="antibiotics-11-00438-f001"><label>Figure 1</label><caption><p>Structures of representative sideromycins and aaRSs inhibitors. The three naturally occurring albomycin congeners differ mainly in C<sub>4</sub> substituent of the pyrimidine nucleoside as indicated. Parts shaded in navy blue indicate the thionucleoside scaffold of albomycins.</p></caption><graphic xlink:href="antibiotics-11-00438-g001" position="float"/></fig><fig position="float" id="antibiotics-11-00438-f002"><label>Figure 2</label><caption><p>Pathway for the biosynthesis of albomycins. (<bold>A</bold>). Genetic organization of gene cluster for the biosynthesis of albomycins in <italic toggle="yes">S. griseus</italic> ATCC 700974. Genes from <italic toggle="yes">abmA</italic> to <italic toggle="yes">abmR</italic> were thought to be required for albomycin biosynthesis. (<bold>B</bold>). Proposed biosynthetic pathway of albomycins. AbmQ was highlighted to show the unusual domain organization. AbmG, a homologue of deoxycytidine kinase, was proposed to be responsible for the formation of <bold>7</bold>. Biosynthetic process from <bold>7</bold> to <bold>12</bold> was believed to be catalyzed sequentially by AbmH, AbmD, AbmF, AbmK, and AbmJ. AbmE and AbmI were responsible for the tailoring modifications of thionucleoside moiety.</p></caption><graphic xlink:href="antibiotics-11-00438-g002" position="float"/></fig><fig position="float" id="antibiotics-11-00438-sch002"><object-id pub-id-type="pii">antibiotics-11-00438-sch002_Scheme 2</object-id><label>Scheme 2</label><caption><p>Chemical synthesis of natural albomycin congeners. A simplified scheme was shown here.</p></caption><graphic xlink:href="antibiotics-11-00438-sch002" position="float"/></fig><fig position="float" id="antibiotics-11-00438-f003"><label>Figure 3</label><caption><p>Structures of synthetic albomycin analogues.</p></caption><graphic xlink:href="antibiotics-11-00438-g003" position="float"/></fig></sec></back></article>